• Most Popular
  • Most Shared

ZymoGenetics gets FDA guidance for trial of Atacicept

Thu Oct 4, 2007 6:21am EDT

Stocks

   

Oct 4 (Reuters) - ZymoGenetics Inc (ZGEN.O) and Merck Serono received official guidance from U.S. health regulators for the design of a clinical trial for their experimental drug to treat damaged kidneys.

The drug, Atacicept, is being tested for treating lupus nephritis, which is characterized by inflammation of the kidneys, ZymoGenetics said in a statement.

This is one of two clinical studies intended to form part of the application for marketing authorization of Atacicept, it added. (Reporting by Aditi Samajpati in Bangalore)



More from Reuters

Photo

Time Warner Cable, Fox at impasse; blackout looms

NEW YORK (Reuters) - About 13 million Time Warner Cable Inc subscribers were to lose most Fox programing at midnight on Thursday unless the cable service provider reached a last-minute deal to pay fees to News Corp to broadcast the shows.

» More Top News
A customer is served at a counter inside a foreign exchange store displaying a poster of various banknotes including the Chinese yuan or renminbi (RMB) in Hong Kong November 20, 2009. REUTERS/Bobby Yip
OUTLOOK 2010:

Be careful what you wish for

Pressure on China to loosen its grip on the yuan will continue but the U.S. should tread carefully. Here are five world market issues to watch.  Full Article 

Global Markets
Clients work out on machines at the Bally Total Fitness facility in Arvada, Colorado June 15, 2009. REUTERS/Rick Wilking

Get real with resolutions

We make them and we break them: The secret to keeping them is to avoid the impossible dream.  Full Article 

Lifestyle